Oncology

Oncology

Branch of medicine

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
National Comprehensive Cancer Network
September 17, 2019
www.prnewswire.com:443
PLYMOUTH MEETING, Pa., Sept. 17, 2019 /PRNewswire/ -- New research in the September 2019 issue of JNCCN--Journal of the National Comprehensive Cancer Network...
Bio Ascend
August 27, 2019
www.prnewswire.com:443
SANTA MONICA, Calif., Aug. 27, 2019 /PRNewswire/ -- Nearly 46 percent of medical school graduates are women, yet women physicians remain underrepresented in...
Reportlinker
Invalid Date
www.prnewswire.com:443
NEW YORK, Feb. 18, 2019 /PRNewswire/ -- This report analyzes the worldwide markets for Nuclear Medicine Imaging Equipment in US$ Thousand by the following...
January 8, 2019
WebWire
AstraZeneca is announcing organisational changes to support continued scientific innovation and commercial success in the main therapy areas as the Company enters a new phase in its strategic development. Included in the changes will be the arrival at AstraZeneca of the world-renowned oncology scientist, José Baselga, as well as the creation of: , , , , , , • Therapy area-focused Research and Development units that are responsible for discovery through to late-stage development - one for BioPh...
December 7, 2018
WebWire
AstraZeneca and MedImmune, its global biologics research and development arm, announced overall survival (OS) results for the Phase III EAGLE trial. EAGLE is a randomised, open-label, multi-centre trial evaluating Imfinzi (durvalumab) monotherapy or Imfinzi in combination with tremelimumab, an anti-CTLA4 antibody, versus standard-of-care (SoC) chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who experienced disease progression follow...
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.